Last updated on May 2012

NAC-MD-01 Hypertension study for patients with stage 1 or stage 2 essential hypertension


Brief description of study

NAC-MD-01 Hypertension study for patients with stage 1 or stage 2 essential hypertension

Detailed Study Description

The current study will evaluate the efficacy and safety of two anti-hypertensives when given as a fixed dose combination and when given as monotherapy for 8 weeks to hypertensive patients with stage 1 or stage 2 essential hypertension.

Patient Inclusion Criteria:
Female or male 18 year of age and above. Currently being treated for hypertension with at least 1 documented DBP value of >90 and <110 systolic in there medical history or at a recent time during pre screening.
Newly diagnosed with essential hypertension who have never received treatment. Must have a mean sitting DBP >95 and <110 at screening.

Patient Exclusion Criteria:
Secondary hypertension, chronic renal disease, severe HTN. Taking more than 4 antihypertension agents. Coronary artery disease requiring treatment with beta-blockers, calcium channel blockers or chronic nitrates.

Clinical Study Identifier: TX135724

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Nasra Hashmi

Coastal Multi-Specialty Research
Santa Ana, CA USA
  Connect »